pancreatic cancer
Conditions
Interventions
Gemcitabine + nab-Paclitaxel regimen (Gemcitabine 1000mg/m2 nab-Panclitaxicel 125mg/2: day1,8,15 28day/course:2-4 course) and operation
Sponsors
Kyushu-Yamaguchi study group of therapy for pancreatobiliary cancer
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically confirmed adenocarcinoma or adenosquamous carcinoma 2) BR-A pancreatic cancer 3) With measurable lesion(s) 4) Without distant metastasis 5) Without any further treatment for pancreatic cancer 6) Age more than 20 or less than 75 7)ECOG Performance Status 0-1 8) Without history of chemotherapy or radiotherapy 9)Adequate organ function 10) Sensory/motor neuropathy: None or Grade 1 11) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Present or previous (within 5 years) double cancer except for carcinoma in situ 2) Pregnant females, possibly pregnant females, females feeding babies and males wishing partners' pregnancy 3) Active infection 4) Severe mental disorder 5) Interstitial pneumonia or pulmonary fibrosis 6) Severe heart disease, liver disease and uncontrolled diabetes 7) Patients positive for HBs antigen 8) Patients inadequate for enhanced CT scan 9) Severe allergy for drugs 10) Patients with inadequate condition
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| R0 resection rate | — |
Secondary
| Measure | Time frame |
|---|---|
| QOL assessment, Effectiveness of preoperative chemotherapy, pathological response rate, incidence rate of adverse events, relative dose intensity | — |
Countries
Japan
Contacts
Public ContactYoshihiro Miyasaka
Kyushu University Department of Surgery and Oncology
Outcome results
None listed